Enorama Pharma AB

ERMA

SE0008216329

Pharmaceuticals

Delayed Nasdaq Stockholm Other stock markets 05:05:21 2024-06-20 EDT			5-day change	1st Jan Change
2.56 ^SEK	-0.39%		+8.47%	-17.42%

05-22	Enorama Pharma AB Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
02-28	Intervacc's Acting CEO Assumes Role Permanently	MT

Enorama Pharma AB announced that it expects to receive SEK 19.926 million in funding from madHat AB

July 16, 2023

Enorama Pharma AB (publ) announced a private placement of 11,070,000 common shares at an issue price of SEK 1.8 per share for the gross proceeds of SEK 19,926,000 on July 17, 2023. The transaction will include participation from new investor madHat AB.

Latest news about Enorama Pharma AB

Enorama Pharma AB Reports Earnings Results for the First Quarter Ended March 31, 2024	05-22	CI
Intervacc's Acting CEO Assumes Role Permanently	02-28	MT
Enorama Pharma AB Reports Earnings Results for the Full Year Ended December 31, 2023	02-21	CI
Enorama Pharma AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02-21	CI
Enorama Pharma AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-22	CI
Enorama Pharma AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-23	CI
Enorama Pharma AB announced that it expects to receive SEK 19.926 million in funding from madHat AB	23-07-16	CI
Enorama Pharma AB Auditor Raises 'Going Concern' Doubt	23-06-08	CI
Enorama Pharma AB Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-31	CI
Enorama Pharma AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022	23-02-15	CI
Enorama Pharma AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-16	CI
Enorama Pharma AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-17	CI
Enorama Pharma AB Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-18	CI
Enorama Pharma AB Auditor Raises 'Going Concern' Doubt	22-04-12	CI
Enorama Pharma AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2021	22-02-16	CI
Enorama Pharma AB Reports Earnings Results for the Full Year Ended December 31, 2021	22-02-16	CI
Enorama Pharma AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-10	CI
Enorama Pharma AB Publ Reports Earnings Results for the First Quarter Ended March 31, 2021	21-05-19	CI
Enorama Pharma AB Auditor Raises 'Going Concern' Doubt	21-04-13	CI
Enorama Pharma AB Publ Reports Earnings Results for the Full Year Ended December 31, 2020	21-02-17	CI
Enorama Pharma AB Auditor Raises 'Going Concern' Doubt	20-04-14	CI
Enorama Pharma AB Auditor Raises 'Going Concern' Doubt	19-04-14	CI
Enorama Pharma AB Auditor Raises 'Going Concern' Doubt	18-04-17	CI
Enorama Pharma AB Auditor Raises 'Going Concern' Doubt	17-04-18	CI
Enorama Pharma AB has completed an IPO in the amount of SEK 10.11 million.	16-05-11	CI

Chart Enorama Pharma AB

Duration

Period

More charts

Company Profile

Enorama Pharma AB is a Sweden-based company, which is primarily involved in the pharmaceutical industry. The Company is mainly focused on the development of medical chewing gum that contains drugs. The Company's product Nicotine gum is a chewing gum contained drugs that help to overcome nicotine addiction. In addition, the medical chewing gum applications include pain management, allergy, cough and cold, among others. The Company distributes its products in Europe through pharmacy chains and grocery stores.

Sector

Pharmaceuticals

Calendar

2024-08-13 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
ENORAMA PHARMA AB	-17.42%	10.09M
SUN PHARMACEUTICAL INDUSTRIES LTD.	+17.17%	43.26B
OTSUKA HOLDINGS CO., LTD.	+17.47%	21.6B
SANDOZ GROUP AG	+21.73%	15.93B
CIPLA LIMITED	+24.05%	15.1B
ZYDUS LIFESCIENCES LIMITED	+58.02%	12.95B
THE MEDICINES COMPANY	-0.05%	6.79B
ONO PHARMACEUTICAL CO., LTD.	-16.22%	6.29B
ASPEN PHARMACARE HOLDINGS LIMITED	+19.77%	6.04B
STADA ARZNEIMITTEL	-8.87%	5.73B